Featured Press Releases

Preclinical study shows NUZ-001 reduces TDP-43 aggregation in ALS

Preclinical study shows NUZ-001 reduces TDP-43 aggregation in ALS

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

  • 23 Jul 2024

MAIA Biotechnology, Inc.a clinical-stage biopharmaceutical company developing targeted...

OCuSOFT Inc. introduces Retaine® Omega Forté™, a liquid supplement designed to deliver superior nutritional support in the management of dry eye

OCuSOFT Inc. introduces Retaine® Omega Forté™, a liquid supplement designed to deliver superior nutritional support in the management of dry eye

Queue Secures $12.6 Million to Launch the World

Queue Secures $12.6 Million to Launch the World's First Fully Autonomous Robotic Pharmacy

AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes

AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes

StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

  • SHARx
  • 04 Aug 2026
Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

  • Triquetra Health LLC
  • 03 Aug 2026
Dallas-Based Microbiome Brand resbiotic® Comes Home to Texas with Launch at H-E-B

Dallas-Based Microbiome Brand resbiotic® Comes Home to Texas with Launch at H-E-B

  • Resbiotic Nutrition, Inc.
  • 03 Aug 2026
US Capital Global Securities Announces $20 Million Offering for Thplasma to Invest in the Future of Plasma Therapeutics

US Capital Global Securities Announces $20 Million Offering for Thplasma to Invest in the Future of Plasma Therapeutics

  • US Capital Global
  • 03 Aug 2026
Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection in two single-dose vial strengths

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection in two single-dose vial strengths

  • Glenmark Pharmaceuticals
  • 30 Jul 2026
EMS and BD expand access to GLP-1 therapies in Brazil by launching semaglutide.

EMS and BD expand access to GLP-1 therapies in Brazil by launching semaglutide.

  • BD (Becton, Dickinson and Company)
  • 29 Jul 2026
The Digital Pharma Advances Conference 2026

Most Popular
August   2026
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.